José Pablo Leone1, Julieta Leone2, Ariel Osvaldo Zwenger3, Julián Iturbe2, Bernardo Amadeo Leone2, Carlos Teodoro Vallejo2. 1. University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA. Electronic address: jose-leone@uiowa.edu. 2. Grupo Oncológico Cooperativo del Sur (GOCS), Argentina. 3. Grupo Oncológico Cooperativo del Sur (GOCS), Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.
Abstract
BACKGROUND: Male breast cancer (MaBC) is an understudied disease; information about locoregional treatment and outcomes in patients with early stage is unknown. We aimed to analyse patient characteristics, locoregional treatment and overall survival (OS) of T1a,b,cN0M0 male breast cancer. METHODS: We evaluated men with T1a,b,cN0M0 breast cancer reported to Surveillance, Epidemiology, and End Results program from 1988 to 2012. Univariate and multivariate analyses were performed to determine the effect of each variable on OS. RESULTS: We included 1263 patients. Median age was 66 years (range 27-103). Median follow-up was 62 months (range 1-294). OS at 5 and 10 years were 85.1% and 66.5%, respectively. Distribution according to tumour sub-stage was: T1a 6.5%, T1b 20.7% and T1c 72.8%. Mastectomy was performed in >74% of patients of each tumour size group and overall 44.1% had >5 lymph nodes examined (LNE). Univariate analysis showed that patients with T1c, no surgery and 0 LNE had worse prognosis. In multivariate analysis, older age (hazard ratio [HR] 11.09), grade 3/4 tumours (HR 1.7), no surgery (HR 3.3), 0 LNE (HR 5.1) and unmarried patients (HR 1.7) had significantly shorter OS. There were no differences in OS between breast conservation versus mastectomy and 1-5 LNE versus > 5 LNE. CONCLUSION: Men with early breast cancer have a favourable OS. However, older age, higher grade, no breast surgery, no LNE and unmarried status emerged as poor prognostic characteristics. Efforts to decrease the high rates of mastectomy and extensive LNE should be taken given similar OS observed with breast conservation and 1-5 LNE, respectively.
BACKGROUND:Male breast cancer (MaBC) is an understudied disease; information about locoregional treatment and outcomes in patients with early stage is unknown. We aimed to analyse patient characteristics, locoregional treatment and overall survival (OS) of T1a,b,cN0M0 male breast cancer. METHODS: We evaluated men with T1a,b,cN0M0 breast cancer reported to Surveillance, Epidemiology, and End Results program from 1988 to 2012. Univariate and multivariate analyses were performed to determine the effect of each variable on OS. RESULTS: We included 1263 patients. Median age was 66 years (range 27-103). Median follow-up was 62 months (range 1-294). OS at 5 and 10 years were 85.1% and 66.5%, respectively. Distribution according to tumour sub-stage was: T1a 6.5%, T1b 20.7% and T1c 72.8%. Mastectomy was performed in >74% of patients of each tumour size group and overall 44.1% had >5 lymph nodes examined (LNE). Univariate analysis showed that patients with T1c, no surgery and 0 LNE had worse prognosis. In multivariate analysis, older age (hazard ratio [HR] 11.09), grade 3/4 tumours (HR 1.7), no surgery (HR 3.3), 0 LNE (HR 5.1) and unmarried patients (HR 1.7) had significantly shorter OS. There were no differences in OS between breast conservation versus mastectomy and 1-5 LNE versus > 5 LNE. CONCLUSION:Men with early breast cancer have a favourable OS. However, older age, higher grade, no breast surgery, no LNE and unmarried status emerged as poor prognostic characteristics. Efforts to decrease the high rates of mastectomy and extensive LNE should be taken given similar OS observed with breast conservation and 1-5 LNE, respectively.
Authors: Siddhartha Yadav; Dhauna Karam; Irbaz Bin Riaz; Hao Xie; Urshila Durani; Narjust Duma; Karthik V Giridhar; Tina J Hieken; Judy C Boughey; Robert W Mutter; John R Hawse; Rafael E Jimenez; Fergus J Couch; Roberto A Leon-Ferre; Kathryn J Ruddy Journal: Cancer Date: 2019-10-07 Impact factor: 6.860
Authors: Daniel Rolf; Khaled Elsayad; Mohamed A M Meheissen; Yasser Elkerm; Carl Opitz; Isabel Radke; Anne Bremer; Anne Hülskamp; Rasha Elsaka; Horeya M Ismail; Essam Elfaham; Abdelsalam Attia Ismail; Hazem Elmansy; Eva Wardelmann; Amr Abdelaziz Elsaid; Barbara Krause-Bergmann; Joke Tio; Hans Theodor Eich; Oliver Micke Journal: Adv Radiat Oncol Date: 2020-02-20